Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) EBIT (2016 - 2023)

Historic EBIT for Cellectis (CLLS) over the last 9 years, with Q3 2023 value amounting to -$20.7 million.

  • Cellectis' EBIT rose 2442.88% to -$20.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$73.4 million, marking a year-over-year increase of 1986.13%. This contributed to the annual value of -$89.7 million for FY2022, which is 15831.86% down from last year.
  • Latest data reveals that Cellectis reported EBIT of -$20.7 million as of Q3 2023, which was up 2442.88% from -$23.6 million recorded in Q2 2023.
  • Cellectis' 5-year EBIT high stood at $14.4 million for Q1 2020, and its period low was -$42.4 million during Q3 2021.
  • In the last 5 years, Cellectis' EBIT had a median value of -$27.3 million in 2022 and averaged -$25.0 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 16233.83% in 2020, then plummeted by 23812.79% in 2021.
  • Over the past 5 years, Cellectis' EBIT (Quarter) stood at -$38.5 million in 2019, then decreased by 1.74% to -$39.2 million in 2020, then surged by 80.4% to -$7.7 million in 2021, then rose by 26.26% to -$5.7 million in 2022, then plummeted by 265.21% to -$20.7 million in 2023.
  • Its EBIT was -$20.7 million in Q3 2023, compared to -$23.6 million in Q2 2023 and -$23.4 million in Q1 2023.